Intellia Therapeutics Inc (NASDAQ:NTLA) was down 4.7% during mid-day trading on Tuesday . The stock traded as low as $17.71 and last traded at $17.73, with a volume of 70,716 shares traded. The stock had previously closed at $18.60.

Several equities research analysts have recently issued reports on NTLA shares. Jefferies Group started coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They issued a “hold” rating and a $33.00 target price on the stock. Leerink Swann assumed coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 target price on the stock. Wedbush assumed coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price target for the company. Finally, Credit Suisse Group AG assumed coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price target for the company.

The company has a 50-day moving average of $22.93 and a 200-day moving average of $24.36. The company’s market capitalization is $632.45 million.

In other news, insider Bros. Advisors Lp Baker bought 200,000 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $3,600,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Carl L. Gordon bought 250,000 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was purchased at an average price of $18.00 per share, with a total value of $4,500,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.